Fred Hutchinson Cancer Research Center and GenoLogics to Collaborate on Developing a Biomedical Informatics Solution
News May 20, 2008
GenoLogics has announced that the Fred Hutchinson Cancer Research Center has selected GenoLogics to collaborate with the company develop an integrated biorepository and biomedical informatics software solution for the Center’s Translational and Outcomes Research group.
The GenoLogics software is being provided to Fred Hutchinson Cancer Research Center by the Canary Foundation, a nonprofit, tax exempt public charity committed to the development of early-detection tests for solid-tumor cancers.
Fred Hutchinson Cancer Research Center focuses on discovering new ways to detect cancers earlier, developing effective treatments with fewer side effects and learning how to prevent cancers from growing in the first place. To connect the clinical and discovery research processes, the Center pursues translational research under its Translational and Outcomes Research group.
“To assist with realizing our vision for translational research, we needed a suite of informatics solutions that enables us to work seamlessly with clinical and laboratory researchers, as well as patients and healthy individuals,” says Dr. Nicole Urban, Head of the Translational and Outcomes Research group.
“Given the importance of collecting the clinical information to achieve this vision, we decided to work with a commercial vendor to provide our biomedical informatics solution. GenoLogics not only has a collaborative approach to developing a solution for us, but our visions around translational research are highly synergistic.”
GenoLogics launched its Biomedical Informatics software solution to address the needs of translational research initiatives to track observational studies, collect patient data at remote sites, provide biospecimen and clinical annotations management and facilitate researchers querying on clinical information and requesting samples.
The suite is comprised of five integrated products: BioVault for biospecimen management; BioChronicle for clinical annotations management; BioQuest to enable Web access; BioSphere for study management; and BioSource to enable electronic patient questionnaires.
“We are very excited to be working with Fred Hutchinson Cancer Research Center as our lead customer to develop our suite of biomedical informatics products,” says Michael Ball, CEO of GenoLogics. “We are developing our new Biomedical Informatics solution to complement our market-leading Research Informatics product line, which together enable research centers to pursue their translational research vision.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.